Cost‐effectiveness
of
second‐line
empagliflozin versus liraglutide for type 2 diabetes in the United States
Diabetes, Obesity and Metabolism(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要